Health & Environmental Research Online (HERO)


Print Feedback Export to File
2064919 
Journal Article 
Aluminium related bone disease and hemodialysis 
Seyfert, UT; Didion, K; Albert, FW 
1987 
1 
The Lancet
ISSN: 0140-6736
EISSN: 1474-547X 
IPA/88/756086 
VOL 2 ISS Aug 22 1987 
REF 5 
eng 
IPA COPYRIGHT: ASHP Serum aluminum (aluminium; I) levels in hemodialysis patients with and without I related bone disease were measured in 9 patients with renal insufficiency and bone symptoms (on hemodialysis for 7-21 yr). The sources of I accumulation were I-containing drugs, I-rich dialysate, and contamination by the tube system. Results showed no significant difference in the basal levels of serum I between 3 patients with I related bone disease and 6 with non-I related bone disease. After the administration of deferoxamine (desferrioxamine; II), a sharp rise in serum I (150 mcg/l) was observed in patients with I related bone disease after 48 h. It was concluded that to prevent the disease advancing and to reach an early diagnosis, II in a dose of 2 g during hemodialysis should be used.